chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the shot around 9:18am on Friday May 7th - felt fine and then at 8:35pm I experienced fever, chills,  stabbing pain in my arm, neck, legs, back, rash on my face/neck-itching, nose drainage and then I had difficulty breathing.   I had shortness of breath and then I would cough.  The coughing continued and was continuous. I would take a deep breath and then I would have a coughing fit.  I couldn't sleep Friday night at all. These symptoms lasted until Sunday morning.  The difficulty in breathing subsided Saturday afternoon but the coughing continued.  On Sunday morning I woke up and my left arm (injection site) and arm pit were swollen and sore. The chills and fever subsided.  The other muscle aches disappeared.  It is Tuesday and slowly the coughing has lessened but it still present along with feeling like having a tight chest.  Nose is still having drainage. The arm pit and injection site being swollen has gone down but is still present. The rash is starting to fade.
Medium sized lump for todays, reddening, soreness at site, then a small raised pustual or hive that has lasted for about a week.  Called to report and turned in records but could not get in touch with provider.
I had a nose infection about two months after receiving the vaccination and I received a steroid shot for it. I had been having normal pregnancy check-ups and everything had been fine. Then, I had a check-up for my pregnancy at week 17 and they were unable to find a heartbeat.
very tired, pain left arm, pain in chest under breast ER, ekg, chest, x-ray chest, ct scan Pulmonary embolism Eliquist
No reaction to the vaccine, clinical staff administered a 12+ non BV dose when a 12+ BV dose should have been administered as a booster.
last Covid vaccine on 1/29/2021.  On Feb 1 I had a racing heart, and saw my PCP on 02/03.  Lab work result was problematic, and the doctor sent me for an Echocardiogram.  My ejection fraction was 20.  Cardiologist sent me immediately to hospital for further dx and to begin treatment.  Had Heart MRI and heart catherterization. Diagnosed with Cardiac Sarcoidosis. I had been diagnosed with stage 1 pulmonary Sarcoidosis in June, 2020.  Stage one required only monitoring.  I was tested again in 11?20 adn pulmonary situation was stable at Stage 1.  I had no symptoms during 2020 and into 2021.  I have a very active lifestyle that included swimming, biking and babysitting a three year old grandson 3x per week.  In January during masked walks I felt some sob, but assumed it was mask wearing.  LIkewise, after receiving vaccine, I felt some fatigue, but it was listed as a side effect, and coupled with our babysitting schedule and the ease of television on cold winter evenings, I thought nothing of the fatigue.  On Feb 2,  after several days of worry, I contacted my doctor with concern that my heart was racing in an unususal way.  Doctor (PCP) saw me, scheduled EKG and labs, and sent me for Echocardiogram which showed ejection fraction at 20.  I was hospitalized for three days of tests and dx of cardiac sarcoidosis.
Within a few minutes began having tingling in my lips and throat. Over approx 20 minutes progressed to feeling of increased throat irritation and pronounced numb/tingly sensation in lips, dry cough.  Within 30 minutes the cough and throat irritation was significant.  Uvula was swollen.  They told me to the ER.  ER started IV and gave me 125mg methyl prednisone, 25 IV benedryl and IV Pepsid.  Cough and mild difficulty with swallow continued approx 30 minutes more and then began to dissipate. Uvula inflammation receded, pulse ox was good, no heart rate issues, no fever.  My voice was nearly gone until 24hrs.  It is improving but my throat is still sore.  No issues at this time with swallowing and voice is at about 3/4 strength.  Pins-n-needles type sensation at the injection site.
vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant product were reported No treatment medication was provided   This case was linked to MOD-2021-395985 (Link).
Delayed menstrual; More than usual cramping; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration on an unknown date (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient medical history reported was not applicable. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. On an unknown date, the patient experienced delayed menstrual, more than usual cramping with nausea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not tested for COVID-19. The clinical outcome of the events delayed menstrual, more than usual cramping with nausea was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Dose administered after freezing temperature excursion; This case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a female patient who received DTPa (Reduced antigen) (Boostrix) (batch number MR5FK, expiry date 21st September 2023) for prophylaxis.   On 17th December 2021, the patient received Boostrix. On an unknown date, unknown after receiving Boostrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.  Additional details were reported as follows: The case was reported by Nurse Practitioner.  The reporter reported that it was discovered that facility's vaccine fridge experienced two alarms in November.  On 19th November 2021, the temperature reached minus 3 degree Celsius for 1 hour and 0.7 degree Celsius for 5 hours.  On 22nd November 2021 the temperature reached 1.0 degrees Celsius for 2 hours.  The reporter reported that it was discovered that the temperature probe had shifted in the fridge and was touching the wall, so reporter believed that might have been the cause of the low readings.  The reporter checked clinic records and discovered that one dose of Boostrix was administered following the freezing temperature reading which led to incorrect storage of drug.  At the time of the report, the dose had not been repeated.  The reporter consented to follow up.
Per patient's report:  She received her first dose of Pfizer COVID-19 vaccine and developed soreness at localized injection site and felt sleepy, otherwise no adverse reaction signs or symptoms patient reported. On 2-19-21 at 2:30 PM she received her second dose of the Pfizer COVID-19 vaccine at a mall.  She reports the lot number of the vaccine was EL9269. She was monitored for 15 minutes after receiving the second dose.  She and her husband left and took the car to a car wash where she fell asleep on her way home and her husband woke her up when they got home.  At about 320 or 3:25 PM, she noticed that her face felt puffy and she had a sensation that her face was sliding down, she developed tongue swelling, blurry vision, dizziness, and she reports that she was talking funny/slurring her words.  Her husband got a flashlight and looked in her throat and said that her throat was swelling.  She felt like falling asleep.  Her husband used her EpiPen on her.  The EpiPen worked right away to improve the symptoms.  She took no other treatments at home.  Her husband drove her to the hospital where she slept the entire way.  She never developed rash, flushing, skin itching, wheezing, coughing, chest tightness, shortness of breath, nausea, vomiting, diarrhea, fevers, chills, or joint pains.  She does not know if she passed out, she states it was hard to stay awake.  She reports having some abdominal cramping and churning for the following 2 to 3 days afterwards.  She was discharged from the hospital ED where she was never admitted.  They gave her an albuterol inhaler to use every 4 hours for 6 days after she left the ED.  She went home at about 10:00 PM and went to bed about 10:30 PM.  She woke up at 3:00 AM crying and then fell back asleep and woke up again around 7:30 AM.  She did not develop any local injection site reactions on her arm this time.
Swollen lymph node; This is a spontaneous report from a contactable physician (patient).  A 43-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), the first dose on 21Dec2020 and the second dose on 11Jan2021 both via an unspecified route of administration at single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced swollen lymph node on an unspecified date with outcome of unknown.  The patient underwent lab tests and procedures which included mammo screen: swollen lymph node on unknown date and ultrasound scan on 11Jan2021 with unknown results as follow-up. A new follow-up was scheduled in 6 weeks. Radiologist suspected side effect from BNT162b2 shots received 21Dec2020 and 11Jan2021.   Information on the Lot/batch number has been requested.
Fever between 100 and 101 degrees F. Headache Body aches Chills Dehydrated
Immed after vaccine - Assoc. c/o feeling "Hot" and was having difficulty swallowing. 12/3/09 Hospital records received for dates 11/17/09. DX: allergic reaction to influenza or/and H1N1 vaccine. Presenting SX: difficulty swallowing, felling like throat was closing, nausea, approx 15 minutes after flu vax and H1N1 vax. Assessment: WNL.  12/7/09 Medical records received for date 11/25/09. DX: back pain, fatigue, idiopathic urticaria, HA. Chief c/o f/u from HA, allergic reaction to either H1N1 vax or seasonal vax. Pt states had vax on same date, and had anaphylactic reaction on same date within 10 minutes. C/o ongoing HA x1yr. sleep disturbance.
This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN (after the first three shots, she felt body aches, soreness) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. Concurrent medical conditions included Diabetes (20 years ago). On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (after the first three shots, she felt body aches, soreness). At the time of the report, PAIN (after the first three shots, she felt body aches, soreness) outcome was unknown. Concomitant medication details were not reported by the reporter. Patient never tested COVID positive. Patient did not received other vaccines within 1 month prior to Moderna COVID-19 vaccine. The adverse event had not caused the patient to seek any form of medical care. Treatment details was not reported by the reporter. This case was linked to MOD-2022-635783 (Patient Link).
Narrative:  12/04/2020 COVID swab, result: not detected COVID infection following COVID vaccine series 03/16, Pfizer, dose #1 04/06, Pfizer, dose #2 08/03 pt cc: cough, fatigue, fever, headache, loss of taste or smell, myalgias, rhinorrhea, sore throat, dyspnea exposure: unknown 08/13 COVID swab, result: detected 08/13 - 8/29 pt symptoms continue 08/13 SARS-COV-2 LINEAGE B.1.617.2 08/13 SARS-COV-2 CLADE 21A DELTA
Rash on upper back and hives present constantly for 4 days starting 4 days after injection then  intermittent over first two weeks especially in evening.  Had to get steroids  After 1 week also noted swollen lymph nodes on entire right side of face sling jaw line up to temple extremely tender  Unable to sleep for two weeks  Finally got steroids again finishing now  Nodes are still slightly tender and palpable entire body aching as well
presented to emergency department for fall at home. He has a past medical history significant for: repeated falls,
Extreme fatigue Chills  Body aches  Felt ?out of it? The above symptoms varied over 4 days  Developed a rash about one week later.
HT looked up vaccine due and circled "TDAP" on PCC as needed/in reality child due for "DTAP" (age 5).  TDAP was given mistakenly.  Hospital said give the DTAP 24 weeks out for TDAP.
This case was reported by a consumer and described the occurrence of injection site pain in a female patient who received SHINGRIX. In January 2018, the patient received the 1st dose of SHINGRIX. In January 2018, less than a day after receiving SHINGRIX, the patient experienced injection site pain, general body pain, fatigue, headache, shivering, fever and nausea. On an unknown date, the outcome of the injection site pain, general body pain, headache, shivering, fever and nausea were unknown and the outcome of the fatigue was not recovered/not resolved. It was unknown if the reporter considered the injection site pain, general body pain, fatigue, headache, shivering, fever and nausea to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient received the dose of SHINGRIX on Friday. The patient had experienced sore injection site, in addition to that on Saturday, general body aches, fatigue, headache, shivers, fever, and slight nausea feeling was also experienced. On Sunday, the patient was better, but still tired. The reporter stated that she did not know if GSK wanted this to be reported or not. In 2 months the patient intended to get the 2nd dose of SHINGRIX. She asked if she should expect the same results. This case was linked to case US2018GSK010904 (husband's case), reported by the same reporter.
Fever for 5 hours, high oral temp of 102.6, controlled with Tylenol. Body aches and headache 18 hours, pain and swelling at injection site- ongoing , blotchy red rash that burns over chest and neck- ongoing. Mild nausea- 8 hours.
had a stroke after receiving the second dose of the Pfizer Covid vaccine for adults; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 65-year-old male patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: CEREBROVASCULAR ACCIDENT (medically significant), outcome "unknown", described as "had a stroke after receiving the second dose of the Pfizer Covid vaccine for adults".  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
(02/17/2021) TIA at the dog park in the morning, Left arm dropped and felt numb. Raced home and had husband take to ER.
I was sneezing and I thought it was allergies. I had a really bad runny nose. My husband had COVID-19 so I took a test and the line appeared bright. I then called the doctor did a telehealth appointment and then he called instead. We talked about how I was sneezing, and he prescribed PAXLOVID. Within two days I started to notice a turnaround from taking the medication. I did get a slight fever 99.4 was the peak.
fever; chills; aches; sick; This case was reported by a physician via call center representative and described the occurrence of fever in a 51-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 23rd October 2019, the patient received the 1st dose of Shingrix. In October 2019, less than a week after receiving Shingrix, the patient experienced fever, chills, pain and sickness. In October 2019, the outcome of the fever, chills, pain and sickness were recovered/resolved.   It was unknown if the reporter considered the fever, chills, pain and sickness to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient's wife. The patient experienced fever, chills, aches, called in sick to work and required bedrest. All above events resolved after 48 hours. The patient's wife claimed that the patient would self report to VAERS and was happy to speak to someone from GlaxoSmithKline safety.
I had COVID 19 Jan 11, 2020 with complete loss of smell for approximately one week.  After one week, my sense of smell returned to normal. 4/27/2021 (13 days after receiving second dose of COVID19 vaccine), I noticed loss of smell.  Not complete, but certain things such as bleach, smoke I was not able to smell.  Other smells were altered, they did not smell as the should.  I went to Urgent care for COVID testing due to loss of smell.  Test was negative.   Loss of smell and smell alterations continued so I went to see ENT provider on Oct 21st, 2021.  He completed additional testing to rule out other causes of loss of smell.  No cause was identified on testing.  I was told to continue "smell training", but has not been helpful. My sense of smell has not returned to normal since receiving 2nd dose of COVID vaccine.
painful it was; 1st dose received in jan 2022, missed my 2nd shot appointment scheduled for Feb 15 2022; got an attack / painful it was; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (Family History) (patient's mother had).   In January 2022, the patient received the 1st dose of Shingrix. On an unknown date, the patient did not received the 2nd dose of Shingrix. In March 2022, between 1 and 3 months after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles. On an unknown date, the patient experienced pain and incomplete course of vaccination. On an unknown date, the outcome of the shingles, pain and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the shingles and pain to be related to Shingrix.     Additional Information: GSK Receipt Date: 14-Sep-2022 Reporter's comment: This case was reported by a patient via interactive digital media. The patient missed his/her 2nd shot appointment which was scheduled for 15th February 2022 and got an attack in March 2022.  Though painful it was not as bad a case as he/she recall from his/her mother when she had it.  The patient question was whether he/she should start over. Additional Supportive Information: Less than 9 months after vaccination the patient had pain. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. Follow-up would not possible as no contact details were available.
A FEW MINUTES AFTER GETTING THE VACCINE, HE DEVELOPED WRINKLES AND RED DISCOLOURATION ON BOTH OF HIS HANDS ON THE DORSAL ASPECT. NO DIFFICULTY BREATHING, OR SHORTNESS OR BREATH OR ITCHING. THE SKIN CHANGES RESOLVED WHILE IN THE MEDICAL TENT.
patient is having a starting dementia; Alzheimer; This spontaneous case was reported by a consumer and describes the occurrence of DEMENTIA (patient is having a starting dementia) and DEMENTIA ALZHEIMER'S TYPE (Alzheimer) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Family history included Alzheimer's disease.    On 05-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DEMENTIA (patient is having a starting dementia) (seriousness criterion medically significant) and DEMENTIA ALZHEIMER'S TYPE (Alzheimer) (seriousness criterion medically significant). At the time of the report, DEMENTIA (patient is having a starting dementia) and DEMENTIA ALZHEIMER'S TYPE (Alzheimer) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment was reported.  Company Comment: This case concerns a  male subject with relevant family history of Alzheimer who experienced the unexpected events of Dementia and Alzheimer's disease. It does not remain clear if the events occured prior of after the first dose of Spikevax. The rechallenge was not applicable as there is only information of the first dose. The medical family history of Alzheimer could be a  risk  factor for the events. The benefit-risk relationship of Spikevax is not affected by this report.; Sender's Comments: This case concerns a  male subject with relevant family history of Alzheimer who experienced the unexpected events of Dementia and Alzheimer's disease. It does not remain clear if the events occured prior of after the first dose of Spikevax. The rechallenge was not applicable as there is only information of the first dose. The medical family history of Alzheimer could be a  risk  factor for the events. The benefit-risk relationship of Spikevax is not affected by this report.
This case was reported by a pharmacist via call center representative and described the occurrence of erythema in an unknown number of patient who received SHINGRIX. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced erythema, swelling and rash. On an unknown date, the outcome of the erythema, swelling and rash were unknown. It was unknown if the reporter considered the erythema, swelling and rash to be related to SHINGRIX. Additional information was received as follows: The age at vaccination was not applicable for this report. The healthcare professional called back in order to talk about case US2018046768, where upon discussion, she started talking about the other patients who received SHINGRIX and experienced erythema and swelling. The pharmacist was asked to collect for more information but she was in rush, as she had a patient at the pharmacy and she hurried to off the call. The healthcare professional reported that the patients had experienced same type of localized reactions were experienced by the patients after getting vaccinated with flu vaccine. This she observed with the flu shot (US2018GSK065237). No further information was provided by her. The reporter stated that the reaction was common and that is why she didn't think of it much. This case was linked to case US2018046768, reported by the same reporter.
Left arm pink, warm to touch going down to elbow and up to shoulder. Started with a rash on 10/19/04 with itching that went away over night. On 10/20/04 woke up with some swelling, redness, heat and spreading.